Asset Details
Do you wish to reserve the book?
Primary pulmonary lymphoepithelioma‐like carcinoma treated with immunotherapy: A case report and literature review
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Primary pulmonary lymphoepithelioma‐like carcinoma treated with immunotherapy: A case report and literature review
Do you wish to request the book?
Primary pulmonary lymphoepithelioma‐like carcinoma treated with immunotherapy: A case report and literature review
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Primary pulmonary lymphoepithelioma‐like carcinoma treated with immunotherapy: A case report and literature review
2022
Overview
Here, we report a case of metastatic Epstein–Barr virus (EBV)‐related primary pulmonary lymphoepithelioma‐like carcinoma (PPLELC) in a young, nonsmoking female who responded well to treatment with two types of immune checkpoint inhibitors (ICIs). This is the first case report of a favorable outcome to ICIs in the late‐line treatment of advanced PPLELC patients with programmed cell death‐ligand 1 (PD‐L1) expression. Primary pulmonary lymphoepithelioma‐like carcinoma (PPLELC) is a rare subtype of non–small‐cell lung cancer. Here, is the first reported case of a favorable outcome to two types of immune checkpoint inhibitors in advanced PPLELC patients with PD‐L1 expression.
Publisher
John Wiley & Sons Australia, Ltd,John Wiley & Sons, Inc,Wiley
Subject
